Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue.

The FDA approved Ozempic to treat kidney disease in Type 2 diabetes patients after trials showed it reduces the risk of ...

Fasting plasma glucose (FPG), age, body mass index (BMI), and male sex are all associated with development of diabe ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...

The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug ...

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...

Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney ...